Abstract:

Objective To investigate the relationship between p53 Arg72pro gene polymorphism and chemoradiotherapy sensitivity of cervical cancer. Methods The cervical cancer patients in ⅡB~ⅣA stage who received concurrent chemoradiotherapy during January 2013 to March 2016 were selected in the study，with their p53 Arg72pro（rs1042522）locus detected by PCR fluorescent probe. The efficacy of concurrent chemoradiotherapy was evaluated by solid tumor RECIST 1.1 standard. Genotype，age，stage，degree of differentiation，tumor size， lymph node metastasis and other factors were included in the Logistic regression model to analyze the influencing factors of the sensitivity of concurrent chemoradiotherapy for cervical cancer，and evaluate the predictive effect of the Logistic model. Results A total of 105 eligible patients were included，with the median follow ⁃up time of 6 months. The genotype of p53 Arg72pro was in line with hardy⁃Weinberg balance，and the multivariate Logistic regression analysis showed that C/G and G/G genotypes increased tumor chemoradiotherapy sensitivity. However， elderly age，low differentiation，lymph node metastasis，tumor > 4 cm and other clinical factors significantly reduced chemoradiotherapy sensitivity（P < 0.05）. Conclusion p53 Arg72pro genepolymorphism is an independent factor in predicting the concurrent chemoradiotherapy sensitivity of cervical cancer，among which C/G and G/G genotypes can increase the chemoradiotherapy sensitivity of tumor. 

Key words:

cervical cancer, p53, rs1042522, genetic polymorphism, chemoradiation sensitivity